Business
Why the Immutep (ASX:IMM) share price will be in focus today
Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday’s trading session up 8.1% to 33 cents.
Immutep is a global biotech that is focused on developing immunotherapy therapies for cancer and autoimmune diseases. Its lead product, eftilagimod alpha, is a soluble LAG-3Ig fusion protein based on the LAG-3 which is in clinical development.
New patent added
The Immutep share price could be on the move today following the company’s latest update released after yesterday’s market close
According to its…
-
Noosa News22 hours agoBroncos’ Adam Reynolds confident of NRL finals return, Raiders’ Josh Papalii injured
-
Noosa News23 hours agoRiverfire spectators face crowd crushes, huge delays on trains and buses
-
Noosa News24 hours agoBig Brother’s Mike Goldman reveals what saved his life after waking up to find Brisbane home engulfed in fire
-
Business24 hours agoWhy is the Super Retail share price tumbling today?